Skip to content

Non-inferiority Clinic of Kollagenase® Compared Iruxol® in Treatment of Cutaneous Ulcers

Study of Non Inferiority of Product Kollagenase ®, Manufactured by Laboratory Cristália When Compared With Iruxol ®, Manufactured by Abbott Laboratory, in the Treatment of Cutaneous Ulcers

Status
Suspended
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00701974
Enrollment
66
Registered
2008-06-19
Start date
2008-02-29
Completion date
2008-02-29
Last updated
2022-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcers

Keywords

Non-inferiority based on efficiency

Brief summary

Skin ulcers can be defined as open injuries, loss of substances with the skin or mucous tissue, caused by disintegration and tissue necrosis. Chronic skin ulcer is any injury that heal in a period not less than 6 weeks. Several etiological causes for the emergence of skin ulcers. Around 73% are venous, arterial are 8%, 3% are diabetic, 2% are traumatic and 14% are from other causes. Clinical studies show that collagenase is an effective drug and presents high tolerabildade in the treatment of ulcerative burns and injuries of various etiologies. Evidence show statistically significant reduction of inflammation, the formation of granulation tissue, decrease in injuries and reepitelization.

Interventions

BIOLOGICALcollagenase (IRUXOL)

patients will be treated with collagenase one time per day.

BIOLOGICALcollagenase (Kollagenase)

patients will be treated with collagenase one time per day.

Sponsors

Azidus Brasil
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients of both sexes aged over 18 years * people with skin ulcers of the lower limbs for at least 3 months

Exclusion criteria

* Lesion with a diameter larger than 12 cm ² * injury over 2 years of evolution; injury infected * neoplastic lesions in activity * poorly controlled diabetes mellitus * HAS poorly controlled * signs of ischemia in the limb * not offset any disease * allergic to components of formula * urticaria * pregnancy * breastfeeding * emotional disturbance

Design outcomes

Primary

MeasureTime frame
Primary: Non-inferiority based on efficiency that will be evaluated by the general improvement of the injury; Secondary: tolerability assessed by the incidence of adverse events.healing

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026